User login
In comments submitted to the NIH regarding the NIH strategic plan, NORD talks about the importance of programs for patients with rare diseases and for undiagnosed patients. NIH has identified advancing research opportunities presented by rare diseases as one of its priorities in its strategic plan. The letter from NORD President and CEO Peter L. Saltonstall congratulates NIH on that position and outlines several components that NORD considers essential to advancing research to develop treatments for rare and neglected diseases. Read the NORD letter.
In comments submitted to the NIH regarding the NIH strategic plan, NORD talks about the importance of programs for patients with rare diseases and for undiagnosed patients. NIH has identified advancing research opportunities presented by rare diseases as one of its priorities in its strategic plan. The letter from NORD President and CEO Peter L. Saltonstall congratulates NIH on that position and outlines several components that NORD considers essential to advancing research to develop treatments for rare and neglected diseases. Read the NORD letter.
In comments submitted to the NIH regarding the NIH strategic plan, NORD talks about the importance of programs for patients with rare diseases and for undiagnosed patients. NIH has identified advancing research opportunities presented by rare diseases as one of its priorities in its strategic plan. The letter from NORD President and CEO Peter L. Saltonstall congratulates NIH on that position and outlines several components that NORD considers essential to advancing research to develop treatments for rare and neglected diseases. Read the NORD letter.
